Arbutus escalates LNP patent battle against Pfizer and BioNTech across North America and EU

Edited by Robert McTiernan··3 min read

Arbutus Biopharma and its exclusive licensee Genevant Sciences have expanded their patent campaign against Pfizer and BioNTech, filing new infringement lawsuits in Canada and the Unified Patent Court that allege unauthorized use of lipid nanoparticle technology underpinning the companies’ COVID-19 vaccines. The infringement actions target the companies’ mRNA-LNP COVID-19 vaccines, alleging unauthorized use of lipid nanoparticle (LNP) delivery technology Arbutus and Genevant are seeking permanent injunctions and monetary damages, including potential recovery of Pfizer/BioNTech’s profits attributable to the alleged infringement.

The filings build on an existing US case in the District of New Jersey covering five patents, meaning Pfizer and BioNTech now face parallel LNP litigation across North America and the EU. Separately, Arbutus disclosed it received approximately $178 million on July 8 as its share of the noncontingent payment under the USD 2.25 billion global settlement reached with Moderna in March 2026.

The Moderna settlement significantly strengthens Arbutus’s position heading into the expanded Pfizer/BioNTech litigation, providing both financial resources and validation that its LNP patent portfolio can command substantial commercial value. However, because the agreement was a negotiated settlement rather than a court judgment, it does not establish a legal benchmark for damages or the outcome of the separate Pfizer/BioNTech cases.

The patents are directed to ionizable lipid compositions and LNP architectures that the plaintiffs argue are fundamental to mRNA delivery. This platform-level claim scope is why the same patent family can be asserted against multiple mRNA vaccine developers independently. The Canadian case seeks a permanent injunction and either damages or an accounting of profits under CA 2,721,333, while the two UPC actions cover EP 4 241 767 and EP 4 495 237 across a bloc that includes Germany, France, Italy, and the Netherlands, among other member states. Genevant, a Roivant Sciences (Nasdaq: ROIV) subsidiary, holds the exclusive license and directs enforcement strategy alongside Arbutus.

The AllSci BriefSystematic R&D and deal news. Daily.

Arbutus’s litigation forms part of a broader web of intellectual property disputes over mRNA and lipid nanoparticle technologies. In addition to Arbutus and Genevant, companies and institutions including Moderna, BioNTech, Sanofi, GSK, Northwestern University and Bayer have asserted patents covering different aspects of mRNA vaccine design or delivery. Recent outcomes have been mixed: Arbutus and Genevant reached a USD 2.25 billion global settlement with Moderna in March 2026, while Alnylam’s infringement case against Pfizer and BioNTech ended in a judgment of non-infringement. Moderna has separately secured favorable infringement rulings against Pfizer/BioNTech in parts of Europe, underscoring that outcomes depend heavily on the specific patents asserted rather than any single judicial view of mRNA technology.

Pfizer and BioNTech’s ALC-0315 lipid is licensed from Acuitas Therapeutics, whose IP traces to the same University of British Columbia research lineage as Arbutus’s patents. The litigation could have broader implications for licensing discussions involving Genevant’s LNP platform, although any commercial impact remains uncertain.

The Canadian and UPC proceedings now begin alongside the existing New Jersey litigation, with no indication from Arbutus of settlement discussions. Together, the cases significantly expand the geographic scope of the company’s enforcement campaign as it seeks to monetize one of the industry’s most closely watched lipid nanoparticle patent portfolios.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/